Table 3.
Group 3 studies—placebo arms of placebo-controlled trials of injectate treatments for knee osteoarthritis.
| WOMAC Peak Effect # | VAS Peak Effect # | WOMAC Scores | VAS Scores | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author/Year/Cohort | Time (Wks) | Δ Score | Exceeds MCID? | Time (Wks) | Δ Score | Exceeds MCID? | # of Joints | Pre-treatment | 3 MO | Δ 3 MO | 6 MO | Δ 6 Mo | Pre-treatment | 3 Mo | Δ 3 MO | 6 MO | Δ 6 Mo |
| Altman 2004 [55] | 12 | 13.2 | Y | NA | NA | NA | 174 | 46.9 | 33.7 | 13.2 | 35.8 | 11.1 | NA | NA | NA | NA | NA |
| Altman 2009 [56] | * | * | Y | NA | NA | NA | 259 | NA | NA | NA | NA | 14.4 | NA | NA | NA | NA | NA |
| Baltzer 2009 [57] | 7 | 13.0 | Y | 7 | 19.6 | N | 99 | 49.6 | 38.2 | 11.3 | 37.8 | 11.8 | 66.3 | 48.8 | 17.5 | 48.2 | 18.1 |
| Bar-Or 2014–10 mL [58] | * | * | Y | NA | NA | NA | 81 | 44.3 | 30.4 | 13.9 | NA | NA | NA | NA | NA | NA | NA |
| Bar-Or 2014–4 mL [58] | * | * | Y | NA | NA | NA | 83 | 42.6 | 29.0 | 13.6 | NA | NA | NA | NA | NA | NA | NA |
| Chao 2010 [53] | 4 | 1.0 | N | NA | NA | NA | 29 | 45.3 | 45.9 | −0.6 | NA | NA | NA | NA | NA | NA | NA |
| Chevalier 2010 [59] | * | * | Y | NA | NA | NA | 129 | 54.6 | NA | NA | 42.4 | 12.2 | NA | NA | NA | NA | NA |
| Henrotin 2017 [60] | NA | NA | NA | 26 | 35.6 | Y | 41 | NA | NA | NA | NA | NA | 66.4 | 36.2 | 30.2 | 30.8 | 35.6 |
| Karlsson 2002 [61] | 12 | 18.2 | Y | 3 | 21.0 | N | 57 | 48.9 | 30.7 | 18.2 | 32.1 | 16.8 | 65.0 | 46.0 | 19.0 | 44.0 | 21.0 |
| Kul-Panza 2010 [62] | 5 | 7.9 | N | 14 | 23.0 | Y | 22 | 70.6 | 63.6 | 7.0 | NA | NA | 65.0 | 42.0 | 23.0 | NA | NA |
| Lee 2015 [63] | 12 | 7.0 | N | 12 | 14.0 | N | 27 | 37.0 | 30.0 | 7.0 | 30.0 | 7.0 | 64.0 | 50.0 | 14.0 | 52.0 | 12.0 |
| Patel 2013 [54] | 6 | −1.2 | N | 6 | 0.0 | N | 46 | 45.5 | 50.7 | −5.2 | 53.1 | −7.6 | 45.7 | NA | NA | 46.1 | −0.4 |
| Ravaud 1999 [64] | NA | NA | NA | 1 | 10.7 | N | 28 | NA | NA | NA | NA | NA | 63.7 | 61.2 | 2.5 | 58.2 | 5.5 |
| Shrestha 2018 [65] | 6 | 14.8 | Y | 2 | 10.3 | N | 58 | 56.5 | 56.1 | 0.4 | NA | NA | 67.3 | 69.0 | -1.7 | NA | NA |
| Smith 2016 [52] | 8 | 15 | Y | NA | NA | NA | 15 | 46 | 37 | 9 | 44 | 2 | NA | NA | NA | NA | NA |
| Takamura 2018 [66] | * | * | Y | NA | NA | NA | 535 | NA | NA | NA | NA | 19.6 | NA | NA | NA | NA | NA |
| Van der Weegen 2015 [67] | 12 | 16.5 | Y | 12 | 9.8 | N | 97 | 40.8 | 22.5 | 16.5 | 28.8 | 12.0 | 24.6 | 14.8 | 9.8 | 21.5 | 3.1 |
| Wu 2018 [68] | 26 | 16.1 | Y | NA | NA | NA | 20 | 28.8 | 13.4 | 14.8 | 12.2 | 16.1 | NA | NA | NA | NA | NA |
| Yavuz 2011 [69] | NA | NA | NA | 1 | 15.0 | N | 30 | NA | NA | NA | NA | NA | 76.0 | 74.0 | 2.0 | NA | NA |
| Mean Scores | 10.0 | 11.0 | 8.4 | 15.9 | 47.0 | 37.0 | 9.2 | 35.1 | 10.5 | 60.4 | 49.1 | 12.9 | 43.0 | 13.6 | |||
| Total # Studies 18/Arms 19 | # of Patients | 1793 | |||||||||||||||
* Only 1 endpoint reported, # Only includes studies that reported two or more follow-up time points.